Objective:

To evaluate the FDA's January 2025 draft guidance for pulse oximeters aimed at improving accuracy across diverse skin pigmentation.

Approach:

• Guidance Overview: The guidance requires validation studies to increase participant cohorts from 10 to 150, with specific representation from darker-skinned individuals.
• Methodological Changes: Introduces objective pigmentation assessment and stricter performance metrics, including a root mean square error threshold.
• Challenges Identified: Potential limitations on market competition and device accessibility due to increased study size; reliance on subjective methods for skin pigmentation classification.

Key Findings:

• The minimum validation cohort is increased to 150 participants, with at least 25% from darker-skinned individuals.
• Spectrophotometry-based measurement is recommended for pigmentation assessment.
• Devices must meet specific performance metrics for accuracy in oxygen saturation measurements.

Interpretation:

Limitations:

• Increased study size may limit market competition and raise costs.
• Manufacturers can conduct their own verification studies, posing potential bias risks.
• Lack of real-world clinical validation and reliance on subjective methods for skin pigmentation classification.

Conclusion:

Sources:

• JAMA Article